Overview
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Status:
Terminated
Terminated
Trial end date:
2008-05-01
2008-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of PfizerCollaborator:
Solvay Pharmaceuticals
Criteria
Inclusion Criteria:- Men, aged 18-50 years old
- Women, aged 18-50 years old
Exclusion Criteria:
- Non-lactating women, aged 18-50 years old
- Non-pregnant women, aged 18-50 years old